On the afternoon of July 17, 2025, a delegation led by Jun Numatani, the mayor of Akita City, Japan, visited Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd. The two sides held fruitful discussions on deepening cooperation in the healthcare sector. The delegation included representatives from several companies, including the medical corporation Apricot Kyokai and Local Power Co., Ltd., fully demonstrating the Japanese side's high regard for cooperation with Suzhou Chung-Hwa Chemical & Pharmaceutical. Suzhou Chung-Hwa Chemical & Pharmaceutical Industrial Co., Ltd. warmly welcomed the delegation. Chairman Wu Suhuan, Deputy General Managers Wang Houjie, Sun Ye, and Liu Yihong, along with other senior management, attended the reception and participated in the discussion.

Demonstrate comprehensive strength and draw a blueprint for cooperation

Zhu Ruwei, Director of Corporate Affairs, led the delegation on a tour of the company's exhibition hall. As a pharmaceutical company invested in mainland China by Taiwan's Sinochem Holdings, the company has focused on the healthcare sector since its establishment in 1993, gradually transitioning from primarily producing antibiotics to becoming a comprehensive pharmaceutical company focused on geriatric and chronic disease medications, including psychiatric drugs and health products. The Japanese delegation gained an in-depth understanding of the company's development history, R&D system, intelligent production lines, and market development strategies.

At the symposium, Chairman Wu Suhuan delivered a speech, extending a warm welcome to the Japanese delegation. Both sides reviewed the important collaboration that took place on April 27th of this year: Suzhou Chung-Hwa Chemical & Pharmaceutical and Local Power Co., Ltd. officially signed a letter of intent for strategic cooperation. The agreement stipulates that Suzhou Chung-Hwa Chemical & Pharmaceutical will produce high-quality medical-grade disinfectant on a contract basis. Through complementary strengths, the two companies will jointly expand the healthcare industry market in China, Japan, and globally. This signing of the letter of intent laid a solid foundation for the technical team's field visit.

Enter the core of scientific research and understand the code of innovation

Afterwards, Ma Xiaohua, director of the company's research institute, led the group on a tour of the R&D center. The company has jointly established the "Cross-Strait Joint Research Institute" with Taiwan's Chung Hwa Research Institute. This collaboration integrates cross-strait research resources, focuses on cutting-edge technologies, and creates a multi-formulation new drug R&D center. Through in-depth collaboration, the company is continuously expanding technological boundaries and promoting the development and industrialization of innovative drugs.

The Japanese technical team made a special visit this time, and their core task was to conduct on-site confirmation and communication on the specific technical standards of the commissioned production, the details of the entire process, and the quality control system.Deputy General Manager Sun Ye led the delegation on a tour of the manufacturing workshop. Technical personnel from both sides conducted in-depth discussions on key aspects such as raw material procurement standards, production environment parameters, aseptic filling processes, and finished product testing indicators. They confirmed technical specifications one by one, clearing technical obstacles for the accelerated implementation of the project. The Japanese delegation expressed their deep appreciation for Suzhou Chung-Hwa Chemical & Pharmaceutical's expertise in production management and quality control, and the smooth progress of technical integration.

Expand cooperation space and deepen strategic consensus

Suzhou Chung-Hwa Chemical & Pharmaceutical has consistently adhered to an international development path. This collaboration vividly demonstrates the complementary strengths of the Chinese and Japanese pharmaceutical and healthcare industries. Going forward, the company will explore further collaborations with Akita City companies in areas such as elderly care and healthcare services, starting with the disinfectant contract manufacturing project.

This exchange has injected new momentum into Sino-Japanese collaboration in the healthcare industry. With the completion of technical integration, the medical-grade disinfectant contract manufacturing project is expected to rapidly enter production. Both parties expressed their commitment to leveraging this collaboration to deepen cooperation across the entire healthcare industry chain and jointly promote the delivery of more high-quality health products and services to the benefit of citizens in both countries.